Could alternating chemo drugs boost survival in biliary cancer?
NCT ID NCT07062536
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tests whether alternating between two chemotherapy regimens (mFOLFOX and mFOLFIRI) works better than using just one (mFOLFOX) as a second-line treatment for advanced biliary tract cancer. The study will enroll 130 adults whose cancer has progressed after first-line treatment. The main goal is to see if the alternating approach improves 6-month survival rates.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
chemotherapy drugs (oxaliplatin, 5FU, leucovorin, irinotecan)
What this could lead to
If successful, this could offer a more effective second-line chemotherapy option for people with advanced biliary tract cancer, potentially improving survival.
What could go wrong
This is a phase 2 trial with only 130 participants, so results are preliminary. Chemotherapy has significant side effects, and the alternating regimen may not prove better than standard treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BILIARY CANCER METASTATIC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Jin Won Kim
Seongnam-si, Out of US, 13605, South Korea